NUBEQA (darolutamide) will be expanded on the PBS to treat patients with metastatic hormone-sensitive prostate cancer, the Govt has announced.
Without subsidy, around 5,000 men might pay more than $40,000 per year for Bayer's Nubeqa.
The PBS listing will mean that from 01 Dec eligible patients will pay a maximum of $30 per script, or just $7.30 if they hold a concession card.
The TGA indication and PBS listing follows results from the Phase III ARASENS trial.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 23
